Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.
Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB. Blauvelt A, et al. Among authors: augustin m. J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1004-1013. doi: 10.1111/jdv.14163. Epub 2017 Mar 31. J Eur Acad Dermatol Venereol. 2017. PMID: 28190255 Free PMC article. Clinical Trial.
Therapy of psoriasis in childhood and adolescence - a German expert consensus.
Sticherling M, Augustin M, Boehncke WH, Christophers E, Domm S, Gollnick H, Reich K, Mrowietz U. Sticherling M, et al. Among authors: augustin m. J Dtsch Dermatol Ges. 2011 Oct;9(10):815-23. doi: 10.1111/j.1610-0387.2011.07668.x. Epub 2011 May 18. J Dtsch Dermatol Ges. 2011. PMID: 21585653 English, German.
A framework for improving the quality of care for people with psoriasis.
Augustin M, Alvaro-Gracia JM, Bagot M, Hillmann O, van de Kerkhof PC, Kobelt G, Maccarone M, Naldi L, Schellekens H. Augustin M, et al. J Eur Acad Dermatol Venereol. 2012 Jul;26 Suppl 4:1-16. doi: 10.1111/j.1468-3083.2012.04576.x. J Eur Acad Dermatol Venereol. 2012. PMID: 22725729 No abstract available.
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M; PSOLAR investigators and Steering Committee. Papp KA, et al. Among authors: augustin m. J Drugs Dermatol. 2012 Oct;11(10):1210-7. J Drugs Dermatol. 2012. PMID: 23134986
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
Reich K, Puig L, Paul C, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Brunori M, Mistry S, Bergmans P, Barker J; TRANSIT Investigators. Reich K, et al. Br J Dermatol. 2014 Feb;170(2):435-44. doi: 10.1111/bjd.12643. Br J Dermatol. 2014. PMID: 24116868 Clinical Trial.
German psoriasis registry PsoBest: objectives, methodology and baseline data.
Augustin M, Spehr C, Radtke MA, Boehncke WH, Luger T, Mrowietz U, Reusch M, Strömer K, Wozel G, von Kiedrowski R, Rustenbach SJ, Purwins S, Reich K. Augustin M, et al. J Dtsch Dermatol Ges. 2014 Jan;12(1):48-57. doi: 10.1111/ddg.12233. J Dtsch Dermatol Ges. 2014. PMID: 24393314
1,188 results